EUCTR2004-000200-40-IT进行中（未招募）不适用
A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.
CB PHARMA0 个研究点目标入组 250 人开始时间: 2005年9月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy OfLevetiracetam In Children With Partial Onset Seizures. - Pediatric Exclusivity Long-term Follow-upEpilepsy - Refractory Partial Onset SeizuresMedDRA version: 7.0Level: LLTClassification code 10061334EUCTR2004-000200-40-CZCB Pharma S.A.255
进行中（未招募）
1 期
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy OfLevetiracetam In Children With Partial Onset Seizures. - Pediatric Exclusivity Long-term Follow-upEUCTR2004-000200-40-HUCB S.A.255
进行中（未招募）
1 期
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures. - Pediatric Exclusivity Long-term Follow-upEpilepsy - Refractory Partial Onset SeizuresMedDRA version: 8.1 Level: LLT Classification code 10061334 Term: Partial seizuresEUCTR2004-000200-40-GBCB S.A.255
进行中（未招募）
不适用
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy OfLevetiracetam In Children With Partial Onset Seizures. - Pediatric Exclusivity Long-term Follow-upEUCTR2004-000200-40-BECB S.A. Pharma Sector250
进行中（未招募）
1 期
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene TherapyHaemophilia BMedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2017-005080-40-GBFreeline Therapeutics Limited50